Contents:

TABLE OF CONTENTS CHAPTER 1 EXECUTIVE SUMMARY 3 Objective of the analysis 3 Scope and focus 3 Our insight into the allergic rhinitis market 4 CHAPTER 2 PATIENT POTENTIAL 13 Patient potential 13 Epidemiology 14 Age variance 15 Global prevalence 16 Methodology 16 US 16 EU 17 Japan 22 Loratadine: the gold standard in allergic rhinitis 23 Associated pharmaceutical markets and indications 24 Asthma and associated market 24 Idiopathic urticaria and associated market 25 CHAPTER 3 GLOBAL MARKET DEFINITION AND OVERVIEW 26 Market definition 26 Global allergic rhinitis market analysis 28 Antihistamine market performance 29 Corticosteroid market performance 30 CHAPTER 4 KEY BRAND ASSESSMENT AND FORECASTING ASSUMPTIONS 32 Key brand strengths and weaknesses 32 Event type one – antihistamine patent expiry 34 Event type two – nasal corticosteroid patent expiry 34 Event type three – new product launch 35 Alvesco (ciclesonide) 35 Drug overview 35 Clinical trial results 35 INS37217 36 Drug overview 36 Trial results 36 Antihistamine analysis 37 Allegra franchise key facts 37 Allegra strategic analysis and forecast assumptions 38 US 39 EU 40 Japan 41 Zyrtec franchise key facts 42 Zyrtec strategic analysis and forecast assumptions 44 US 45 EU 46 Japan 46 Xyzal key facts 47 Xyzal strategic analysis and forecast assumptions 48 US 50 EU 50 Japan 50 Clarinex key facts 51 Clarinex strategic analysis and forecasting assumptions 52 US 53 EU 53 Japan 54 Ebastel analysis 55 Ebastel strategic analysis and forecasting assumptions 56 US 57 EU 57 Japan 58 Corticosteroid analysis 59 Nasonex key facts 59 Nasonex strategic analysis and forecasting assumptions 59 US 61 EU 62 Japan 62 Rhinocort analysis 63 Rhinocort strategic analysis and forecasting assumptions 64 US 66 EU 66 Japan 66 Flonase analysis 67 Flonase strategic analysis and forecasting assumptions 68 US 69 EU 70 Japan 70 Nasacort analysis 71 Nasacort strategic analysis and forecasting assumptions 72 US 74 EU 75 Decongestant analysis 75 Decongestant market performance 75 Oral delivery 75 Nasal delivery 75 CHAPTER 5 ENVIRONMENTAL ASSESSMENTS 76 Current and future opportunities and threats in the allergic rhinitis market 76 US: opportunities and threats 76 Opportunities 77 Threats 77 Japan: opportunities and threats 79 Opportunities 80 Threats 81 EU: opportunities and threats 81 Opportunities 81 Threats 82 EU country-specific demographics 82 CHAPTER 6 CASE STUDIES 88 Case study one – Impact of regulatory change on patent protection for allergic rhinitis treatment 88 Frivolous patents or genuine discoveries? 88 New patents no longer protect old drugs 88 Regulatory positions on generic approvals 92 US 92 EU 92 Japan 93 Case study two – Variation in degree of country-specific generic erosion for antihistamines and corticosteroids 94 US 94 EU 99 France 99 Germany 100 Italy 102 Spain 105 UK 107 Japan 109 Case study three – Impact of Rx to OTC switches in the US allergic rhinitis market 111 Managed care organizations and insurance companies 112 Pricing strategies and co-payments 113 Case study four – Physician specialty 116 Definition of allergic rhinitis prescriptions 116 Physician specialty 116 Prescription numbers 120 APPENDIX A – INTERVIEW TRANSCRIPTS 121 Opinion leader biographies 121 US opinion leader 122 Patient demographics 122 Antihistamines 123 Corticosteroids 125 Brand Specific opinions 126 Combinations with decongestants 127 Future challenges in Allergic rhinitis 128 German opinion leader 129 Patient demographics 129 Antihistamines 130 Corticosteroids 132 Combinations with Decongestants 133 US opinion leader 134 Patient demographics 134 Antihistamines 137 Corticosteroids 139 Brand Specific opinions 140 Combinations with decongestants 141 Future challenges in Allergic rhinitis 142 UK opinion leader 143 Patient demographics 143 Antihistamines 144 Corticosteroids 146 APPENDIX B 148 Bibliography 148 Epidemiology 148 Clinical trial data 149 Other 150 Report methodology 151 Our 152 Our Healthcare 152 Our Healthcare research and analysis methodologies 153 Our Healthcare therapy area capabilities 153 Disclaimer 154